Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 8Neoplasms 4Recurrence 2Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Renal Insufficiency 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hepatic Insufficiency 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × copanlisib × Clear all
NCT05217914 2024-10-24

A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions

Bayer

Completed
6 enrolled

Recurrence

NCT03458728 2023-12-04

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Bayer

Phase 1/2 Terminated
31 enrolled 17 charts
CNSLymphoidSarcoma

Lymphoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡